WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT

Product: CheckNOW HIV SELF TEST WHO reference number: PQDx 0481-032-00

CheckNOW HIV SELF TEST with product code 29012-W01, manufactured by Abbott Rapid Diagnostics Jena GmbH (former Alere Technologies GmbH), Rest of World regulatory version, was accepted for the WHO list of prequalified in vitro diagnostics and was listed on 4 April 2022.

Summary of WHO prequalification assessment for CheckNow HIV SELF TEST

	Date	Outcome
Prequalification listing	4 April 2022	listed
Dossier assessment	8 February 2022	MR
Site inspection(s) of quality	16-18 July 2018	MR
management system		
Product performance	3 rd and 4 th quarter 2021	MR
evaluation		

MR: Meets Requirements

Report amendments and/or product changes

This public report has since been amended. Amendments may have arisen because of changes to the prequalified product for which WHO has been notified and has undertaken a review. Amendments to the report are summarized in the following table below.

Version	Summary of amendment	Date of
		report
		amendment
2.0	Updating of product's shelf life from 18 to 24 months and	17 June
	updating the zip-lock pouch label with the current version in	2022
	the public report.	

Intended use

According to the claim of intended use from Abbott Rapid Diagnostics Jena GmbH, "The CheckNOW HIV SELF TEST is a single-use, in vitro (outside the body) visually read rapid immunoassay that uses a blood sample from a finger puncture for the qualitative detection of antibodies to HIV-1 and HIV-2 in blood. The CheckNOW HIV SELF TEST is intended to be used manually by untrained lay users (self testing) who are 14 years older to aid in the

diagnosis of HIV-1 or HIV-2 infection. This test is not intended to be used as an HIV screening test for blood donation."

Assay description

According to the claim of assay description from Abbott Rapid Diagnostics Jena GmbH, "HIV is recognized as the virus that causes AIDS (Acquired Immunodeficiency Syndrome). The virus is transmitted by sexual contact, exposure to infected blood, certain body fluids or tissues, and from mother to child during pregnancy The CheckNOW HIV SELF TEST detects the presence of antibodies to HIV-1 and/or HIV-2 in blood. The product includes a Test device and a Buffer. To use the test, two drops of blood sample are collected from the fingerstick in the Basin of the plastic cover. One drop of blood is transferred by a Specimen dropper to the Well. After that, one drop of Buffer is applied. When the test is completed, two lines can appear on the device. The red line in the Control Line (C) area will only become visible if the added blood sample and/or buffer have moved over the T/C Line areas of the reading window. The T line area is precoated with HIV-1 antigen glycoprotein 41 and HIV-2 antigen glycoprotein 36. The red line in the Test Line (T) area will only become visible if the applied sample contains antibodies to HIV-1 or HIV-2."

Test kit contents

Component	1 test
	(product code 29012-W01)
Test device	1
Alcohol pads (sterile)	2
Plaster (sterile)	1
Buffer	1
Specimen dropper	1
Sterile lancet	1
Instructions for use	1

Items required but not provided

- Timer
- Tissue

Storage

The test kit should be stored at 2-30°C.

Shelf-life upon manufacture

24 months.

Warnings/limitations

Refer to current version of manufacturer's instructions for use.

Prioritization for prequalification

Based on the established eligibility criteria, the CheckNow HIV SELF TEST was given priority for WHO prequalification assessment.

Dossier assessment

Abbott Rapid Diagnostics Jena GmbH submitted a product dossier for CheckNow HIV SELF TEST as per the "Instructions for compilation of a product dossier" (PQDx_018 version 3). The information (data and documentation) submitted in the product dossier was reviewed by WHO staff and external technical experts (assessors) appointed by WHO.

The manufacturer's responses to the nonconformities found during dossier screening and assessment findings were accepted on 8 February 2022.

Commitment for prequalification

Commitment to Prequalification 1: Please provide real-time stability study final report TR20077 by 31 August 2022. Commitment was fulfilled. Issue closed.

Based on the product dossier screening and assessment findings, the product dossier for CheckNow HIV SELF TEST meets WHO pregualification requirements.

Manufacturing site inspection

An inspection of Abbott Rapid Diagnostics Jena GmbH (former Alere Technologies GmbH) located at Loebstedter Str. 103-105, Jena, Germany was conducted from 16th to 18th of July 2018. At the time of considering the product application for Prequalification, the Manufacturer of the product had a well-established quality management system and manufacturing practices in place that would support the manufacture of a product of consistent quality. Routine inspections of the Manufacturing site will be conducted with copies of the WHO Public Inspection Report (WHOPIR) published on the WHO Prequalification web page as per Resolution WHA57.14 of the World Health Assembly. Note that a WHOPIR reflects the information on the most current inspection performed at a manufacturing site for *in vitro* diagnostic products and gives a summary of the inspection findings.

The manufacturer's responses to the nonconformities found at the time of the inspection were accepted on 20th of December 2018.

Product performance evaluation

CheckNOW HIV SELF TEST was evaluated by the KEMRI CGHR HIV Research laboratory, Kenya, on behalf of WHO in the 3rd and 4th quarter of 2021, according to protocol PQDx_241, version 5.

Clinical performance evaluation

In this limited laboratory-based evaluation of clinical performance characteristics, a panel of 1000 capillary blood specimens was used. Plasma specimens collected simultaneously were characterized using the following reference algorithm: AiD anti-HIV 1+2 ELISA (Beijing Wantai Biological Pharmacy Enterprise Co., Ltd) and Murex HIV Ag/Ab Combination (DiaSorin Dartford, United Kingdom); followed by INNO-LIA HIV I/II Score (Fujirebio).

Clinical performance characteristics in comparison with an agreed reference standard		
Sensitivity* %	99.5% (95% CI: 98.2-99.9)	
(N=400)		
Specificity %	98.5% (95%CI: 97.2-99.3)	
(N= 600)		
Invalid rate %	0	
(N= 0)		
Inter-reader variability %	0	
(N= 0)		

^{*} Seven of the 398 (1.8%) reactive results on the HIV-positive clinical panel were graded as very weak lines.

Analytical performance evaluation

Analytical performance characteristics		
Sensitivity during seroconversion	Of a total of 34 specimens, 13 were detected by the	
on 5 seroconversion panels in	CheckNOW™ HIV SELF TEST; versus 10 specimens	
comparison with a benchmark	detected by Wantai AID anti-HIV 1+2 ELISA.	
assay (Wantai AID anti-HIV 1+2	Seroconversion sensitivity index of -0.6, therefore	
ELISA)	detection is -0.6 specimens earlier than Wantai AID	
	anti-HIV 1+2 ELISA.	
Analytical sensitivity on a mixed	20 of 20 specimens were correctly classified.	
titer panel (0800-436)		
Analytical sensitivity on WHO	All 6 types/subtypes included in the panel were	
reference preparation panel(s)	detected (although subtype HIV-1 O with a very	
(NIBSC Code 02/210)	weak line)	
Lot to lot variation on a dilution	Lot to lot variation was within +/- 1 two-fold	
panel	dilutions for 6 dilution series and ≥ 2 two-fold	
	dilution for 4 dilution series.	

Operational characteristics and ease of use

The assay was found easy to use by the operators performing the evaluation.

Key operational characteristics		
Specimen type and volume	One drop of capillary whole blood is needed for the test, but 2 drops are collected for the procedure	
Number of steps*	3 steps in total	
	0 steps with precision pipetting	
Time to result	15 minutes	
Endpoint stability (interval)	5 minutes (the test can be read between 15 and 20 minutes after addition of diluent)	
Internal QC	Yes – reagent addition control	

^{*} Definition: each action required to obtain a result (excluding specimen collection, device preparation – opening the pouch), e.g. for RDTs: add specimen, add buffer (2 steps).

Based on these results, the performance evaluation for CheckNOW HIV SELF TEST meets the WHO prequalification requirements.

Limitations of the performance evaluation:

- 1. All specimens used in the performance evaluation were from the same geographical area.
- 2. All positive specimens in the performance evaluation were positive for HIV-1, so the sensitivity of CheckNOW HIV SELF TEST for the detection of HIV-2 could not be assessed.

Labelling


- 1. Labels
- 2. Instructions for use

June 2022, version 2.0

1. Labels


1.1 Zip-lock pouch label

Front



1.2 Test device pouch





1.3 Test device image



1.4 Buffer label




1.5 Sterile lancet label



1.6 Alcohol swab label



1.7 Specimen dropper label



1.8 Plaster



2. Instructions for use¹

_

¹ English version of the IFU was the one that was assessed by WHO. It is the responsibility of the manufacturer to ensure correct translation into other languages.





Revision Date: 2022-03-31

INSTRUCTIONS FOR USE

Catalog Number: 29012-W01

Before testing you must read all the steps. Conformance with the test procedure is necessary to ensure an accurate result. Precautions

Do not use

- If you have a bleeding disorder
- If you are on HIV treatment (ARVs) If you are needle phobic
- If the kit bag or components is broken
- If the kit or components have been used If your area is under poor lighting

Do not eat or drink while you perform the test

STEP 1: PREPARATION

Prepare a Timer and Tissue.

Not included in the kit, but needed.

Open and place all materials on a flat and clean surface with bright light. (B) 2 Alcohol Pads Specimen Dropper ш A Test device

Wash hands in warm water and dry. If no water and dry. If no warm water is available,

G Use kit bag

D Buffer

Plaster

O

Lancet stenten

Œ

Choose ring finger or Chocat middle finger. rub your hands together.

Avoid dominant hand.

96


A It only pricks once!

STEP 2: COLLECT BLOOD

Massage and rub your hand & finger to increase circulation.

Clean your finger with (B) Alcohol Pad. Let it dry for

10 seconds.



It only pricks once! Remove the Lancet cover. Needle inside

Press the (F) Lancet against the finger until it clicks. PRESS HARD CLICK 00

Massage from the base to the tip, let 2 drops of blood fall into the Basin. If you are having difficulty, wipe finger clean and squeeze again.



apply the © Plaster. If needed, press Wipe finger with (B) Alcohol Pad and Start next step immediately to transfer on the plaster to stop bleeding.



STEP 3: TEST

Dropper all the way down and hold Squeeze the top of the E Specimen while dipping into the blood sample.

Squeeze


release slowly to draw blood into the dropper. Dip the dropper into the blood in Basin and Avoid bubbles when drawing blood.

Place dropper over the Well labelled S. Squeeze the top of the dropper to apply 1 drop of blood into the Well labelled S.



1 Drop **Slow** Squeeze

labelled S.




Start the Timer. Read the result in 15-20 minutes, Start the Timer. Read the resol do not read past 20 minutes.



Number: 1156182105 See flip side for STEP 4: Read Result

STEP 4: READ RESULT

Read test result in 15-20 minutes.



NON-REACTIVE (=Negative)



There is no line in the T area. The test did not detect the presence of HIV, however very recent exposure A line appears only in the C area. cannot be excluded.

SELF-TEST HERE

It is recommended to conduct a retest after 6 weeks from atest risk of exposure to HIV.

REACTIVE (=Positive)



One line in the C area, together with one line in the T area, no matter how faint, indicates the potential to be HIV positive.



A reactive result must be confirmed by a lab test. Protect yourself and others! Avoid any activity that could transmit Consult a health care provider.

TEST DID NOT WORK (=lnvalid)

Seal the kit bag tightly.

Place all used components

STEP 5: DISPOSAL

back into the kit bag.



If no line appears in the C area, even if a line appears in the T area, the test did Test again using a new kit or

consult a health care provider.



Throw away the kit bag in waste bin

or household rubbish.

Dispose in accordance to local regulations

The CheckNOW" HIV SELF TEST is a single-use, in vitro (outside the body) visually read rapid immunoassay that uses a blood sample from a finger puncture for the qualitative detection of antibodies to HIV-1 and HIV-2 in blood. The CheckNOW™ HIV SELF TEST is intended to be used manually by untrained lay users (self testing) who are 14 years and older to aid in the diagnosis of HIV-1 or 4IV-2 infection. This test is not intended to be used as an HIV screening test for blood donation.

SUMMARY

only become visible if the applied sample contains antibodies to HIV-1 or HIV-2. 4IV is recognized as the virus that causes AIDS (Acquired Immunodeficiency Syndrome). The virus is transmitted by sexual contact, exposure to infected blood, certain body fluids or tissues, and from mother to child during pregnancy. f the added blood sample and/or buffer have moved over the T/C Line areas of the reading window. The Tline area is precoated with HIV-1 antigen glycoprotein The CheckNOW" HIV SELF TEST detects the presence of antibodies to HIV-1 and/or HIV-2 in blood. The product includes a Test device and a Buffer. To use the test, two drops of blood sample are collected from the fingerstick in the Basin of the plastic cover. One drop of blood is transferred by a Specimen dropper to the Well. After that, one drop of Buffer is applied. When the test is completed, two lines can appear on the device. The red line in the Control Line (C) area will only become visible 41 and HIV-2 antigen glycoprotein 36. The red line in the Test Line (T) area will

TORAGE

- Store the test kit at 2-30°C (36-86° F) until the expiry date. Do not freeze.
 - Do not use the test kit after expiry date printed on the test pouch. Do not open the sealed foil test pouch until you are ready to use the test.
- The buffer is for single-use, and should be used within one hour after cap open. Test device should be used within one hour after the pouch has been opened.
 - **WARNINGS AND PRECAUTIONS**
- This test may give an unexpected positive result. Whether the result is positive or negative, you should consult with your doctor before making medical decisions. For in vitro diagnostic use only.

HIV to others.

- plasma sample. The test device is recommended to be used at room temperature (15-30°C). Lancet and Specimen dropper are for single-use only. Do not reuse.
- · If you do not understand the IFU please reach out to provided Technical Service contact.
- area does not confirm sufficient specimen addition. You must transfer exactly TEST PERFORMANCE If your test is working, you will see a line in the Control Line area on your test device. If there is no line in the Control Line area, your test did not work, and the test result is invalid. However, the presence of a line in the Control Line

cytomegalovirus

- Keep the SELF TEST and the components out of the reach of children. I drop of blood to the Well before adding Buffer.
- The buffer contains 0.09% sodium azide as a preservative, which may be toxic care persons to correctly identify 99.9% (2097) out of 2100) with a confidence if ingested. If you get contaminated to your eyes rinse with running water for interval of 99.6% to 100% of HIV negative samples (known as the test's specificities in first action persists, get medical attention.

 1) Further in field clinical evaluations conducted in South Africa, Congo, Vietnam
 - If your finger is still bleeding, use tissue on wipes. Protect yourself and others, and Spain, the test correctly identified 99.6% (1824 out of 1831) with a confidence Finger prick blood should be transferred from Basin to Well immediately to interval of 99.2% to 99.9% of HIV negative samples when performed by first time avoid blood clotting (within 2 minutes).

IMITATIONS OF THE TEST

- The CheckNOW" HIV SELF TEST is designed to be used with a finger leaves providence interval of 99.5% to 100% of HIV positive samples (known as the test's
 - Not suitable for testing infant younger than 18 months?

 A NON-REACTIVE (Negative) result does not absolutely rule out the Vietnam and Spain, the test correctly identified 95.1% (270° out of 284) with a NON-REACTIVE (Negative) result does not absolutely rule out the Vietnam and Spain, the test correctly identified 95.1% (270° out of 284) with a puncture blood sample. Other body fluids must not be used.
 - possibility of HIV infection.

 A REACTIVE (Positive) result must be confirmed by a health care provider first time self test users.
- using appropriate confirmatory testing.
 The intensity of the Test Line for a REACTIVE (Positive) result does not excluded from this analysis as they were observed to dery an unexpected result.
 - reflect how much HIV antibody is present in the blood sample.
- Although it's rare, false results may occur. If you have concerns that your result To ensure that other medical conditions (potential cross-reactants) do not affect may be false, please contact your health care provider. Refer also to warnings and precautions about the use of this test.
 - Biotin concentrations up to 1500 ng/mL may lead to decreased Control Line negative blood were tested from people who had other conditions. These includ
 - ed 250 specimens from pregnant women and 342 other specimens as follows: intensity but have no impact on the internal control performance.

Manufacturer

Do not reuse Batch code

 \otimes

Consult instruc-tions for use Use-by date

(•=(

Store between 2-30°C

Catalogue number In vitro diagnostic medical device

<u>N</u> REF

HAMA; Multiparous woman, Elevated IgG; Elevated IgM; Systemic lupus erythematosus; Hemolytic; Lipemic; Icteric; Rheumatoid Factor; ANA; Anti-E. coli positive specimens; Sickle-cell disease specimens; Blood from recipients of multiple blood transfusions; HBsAg; EBV; CMV; Malaria; Measles; Tuberculosis; Perform test only by using a fresh blood sample. Not to be used with serum or • An incorrect or "false" NON-REACTIVE (Negative) result; an occur for any plasma sample.

The test device is recommended to be used at room temperature (15-30°C). Instructions for Use carefully; If you are on HIV treatment (ARV)^{3/3,2}; If you . An incorrect or "false" REACTIVE (Positive) result can occur for any of the following reasons: Incorrectly reading test result; Not following the Instructions for Use carefully; Having received an HIV vaccine; In cases of infection with were very recently infected; The presence of bubbles during sample application, in particular in low positive samples.

These non-HIV medical conditions did not affect the performance of CheckNOW" HIV SELF TEST with exception of the observed cross-reactivity Varicella zoster virus; Influenza Å and B; Tick borne encephalitis; Influenza recipient, Leishmaniasis positive; Syphilis; Toxoplasmosis; Helicobacter pylori; vaccine recipient; Human African trypanosomiasis; Yellow fever virus; Post-immunization measles; Vaccine-induced HIV seropositivity; Yellow fever vaccine HSV; anti-HCV, anti-HBs, anti-HBc; anti-HTLV-1/2; anti-HEV, anti-HAV seen with 2 out of 21 tested cytomegalovirus (CMV) specimens. The test has been shown in clinical evaluations performed by professional health

The CheckNOW" HIV SELF TEST was also evaluated with 23 interfering spiked with HIV-1 Antibody positive plasma and the test results indicated these substances which include medicine and blood analyte. These substances were interference substances did not affect the performance of the CheckNOW

LITERATURE REFERENCES HIV SELF TEST.


The test has also been shown in clinical evaluations performed by professional

self test users.

- 1. Blattner, W., Gallo, R., & Temin, H. HIV causes AIDS. Science. 1988 241(4865), 515-515.
 - 2. CDC: 2008 Case Definition; Human Immunodeficiency Virus Infection.
- 3. Delaney KP, Branson BM, Uniyal A, et al. Evaluation of the Performance Characteristics of 6 Rapid HIV Antibody Tests. Clinical Infectious Diseases 2011; 52(2): 257-263. sensitivity). Further in field clinical evaluations conducted in South Africa, Congo, confidence interval of 91.9% to 97.3% of HIV positive samples when performed by
- roviral Therapy. Journal of Clinical Microbiology. 2003; 41(5): 2153-2155.
 5. O'Connell RJ, Agan BK, Anderson SA, et al. Sensitivity of the Multispot 4. O'Connell RJ, Merritt TM, Malia JA, et al. Performance of the OraQuick Rapid Antibody Test for Diagnosis of Human Immunodeficiency Virus Type Infection in Patients with Various Levels of Exposure to Highly Active Antiret *Note: A total of 6 first time CheckNOW™ HIV SELF TEST users needed to be
 - HIV-1/HIV-2 Rapid Test Using Samples from Human Immunodeficiency Virus Type 1-Positive Individuals with Various Levels of Exposure to Highly Active Antiretroviral Therapy. Journal of Clinical Microbiology Abbott Rapid Diagnostics Jena GmbH Orlaweg 1, D-07743 Jena, Germany www.abbott.com/poct



referenced are trademarks of either the Abbott group ©2022 Abbott. All rights reserved. All trademarks



Email: ARCIS.techsupport@abbott.com

Email: LA.techsupport@abbott.com Email: LA.techsupport@abbott.com

Email: TW.techsupport@abbott.com Email: AP.techsupport@abbott.com

Tel. +617 3363 7100 Tel. 00801 128036 Tel. +7 499 403 9512 Tel. +57 1482 4033 Tel. 0800 111 3363 Europe & Middle East Tel. +44 161 483 9032 Tel. +27 10 500 9700 **TECHNICAL SUPPORT** Taiwan Russia & CIS Latin America Brazil Asia Pacific

Sterilized using ethylene oxide Sterilized using irradiation

STERILE EO STERILE R 3

Caution

Contains sufficient for <n> tests

LoT